Tolterodine does not affect memory assessed by passive-avoidance response test in mice
Autor: | Gregg D. Cappon, Donald Newgreen, Richard H. Alper, Brian Bush, Gregory L. Finch |
---|---|
Rok vydání: | 2008 |
Předmět: |
Male
medicine.medical_specialty Tolterodine Tartrate Side effect Phenylpropanolamine Scopolamine Central nervous system Muscarinic Antagonists Pharmacology Cresols Mice Random Allocation Species Specificity Memory Internal medicine Muscarinic acetylcholine receptor Avoidance Learning medicine Animals Benzhydryl Compounds Oxybutynin Dose-Response Relationship Drug Memoria medicine.disease Endocrinology medicine.anatomical_structure Overactive bladder Tolterodine Psychology medicine.drug |
Zdroj: | European Journal of Pharmacology. 579:225-228 |
ISSN: | 0014-2999 |
DOI: | 10.1016/j.ejphar.2007.10.063 |
Popis: | Antimuscarinics are first-line pharmacotherapy for the treatment of overactive bladder. However, because central nervous system cholinergic neurotransmission is involved in cognition, and the central nervous system-permeable antimuscarinics scopolamine and oxybutynin affect memory, cognitive impairment has been noted as a possible side effect of these drugs. We evaluated the effect of tolterodine, an antimuscarinic for overactive bladder, in a mouse passive-avoidance model of memory. Mice were chosen because like humans, mice but not rats, form the pharmacologically active 5-hydroxymethyl metabolite of tolterodine, DD01. In the passive-avoidance test, tolterodine at 1 or 3 mg/kg had no effect on memory; the latency to cross and percentage of animals crossing were comparable to controls. In contrast, scopolamine induced a memory deficit; the latency to cross was decreased, and the number of animals crossing was increased. Therefore, at a dose exceeding therapeutic exposure by six-fold, tolterodine had no effect on memory in the mouse passive-avoidance model, indicating that tolterodine does not disrupt cognitive function in this testing paradigm. |
Databáze: | OpenAIRE |
Externí odkaz: |